89 related articles for article (PubMed ID: 20035038)
21. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies.
Zia-Amirhosseini P; Hurd DD; Salfi M; Cheah TC; Aycock J; Cesano A
Pharmacotherapy; 2007 Oct; 27(10):1353-60. PubMed ID: 17896890
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
23. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.
Vanholder R; Camez A; Veys N; Van Loo A; Dhondt AM; Ringoir S
Thromb Haemost; 1997 Apr; 77(4):650-5. PubMed ID: 9134637
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers.
Kim TE; Kim BH; Kim J; Kim KP; Yi S; Shin HS; Lee YO; Lee KH; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Oct; 31(10):2249-57. PubMed ID: 19922896
[TBL] [Abstract][Full Text] [Related]
26. A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients.
Perry SL; O'Shea SI; Byrne S; Szczech LA; Ortel TL
Thromb Haemost; 2006 Dec; 96(6):750-5. PubMed ID: 17139369
[TBL] [Abstract][Full Text] [Related]
27. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults.
Musson DG; Kramer WG; Foehr ED; Bieberdorf FA; Hornfeldt CS; Kim SS; Dorenbaum A
Clin Ther; 2010 Feb; 32(2):338-46. PubMed ID: 20206791
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis.
Tsaganos T; Kouki P; Digenis P; Giamarellou H; Giamarellos-Bourboulis EJ; Kanellakopoulou K
Int J Antimicrob Agents; 2008 Jul; 32(1):46-9. PubMed ID: 18534825
[TBL] [Abstract][Full Text] [Related]
29. Rilonacept in the treatment of chronic inflammatory disorders.
McDermott MF
Drugs Today (Barc); 2009 Jun; 45(6):423-30. PubMed ID: 19649332
[TBL] [Abstract][Full Text] [Related]
30. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.
Goldbach-Mansky R; Shroff SD; Wilson M; Snyder C; Plehn S; Barham B; Pham TH; Pucino F; Wesley RA; Papadopoulos JH; Weinstein SP; Mellis SJ; Kastner DL
Arthritis Rheum; 2008 Aug; 58(8):2432-42. PubMed ID: 18668591
[TBL] [Abstract][Full Text] [Related]
31. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.
Klein AL; Imazio M; Cremer P; Brucato A; Abbate A; Fang F; Insalaco A; LeWinter M; Lewis BS; Lin D; Luis SA; Nicholls SJ; Pano A; Wheeler A; Paolini JF;
N Engl J Med; 2021 Jan; 384(1):31-41. PubMed ID: 33200890
[TBL] [Abstract][Full Text] [Related]
32. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS).
Hoffman HM
Expert Opin Biol Ther; 2009 Apr; 9(4):519-31. PubMed ID: 19344287
[TBL] [Abstract][Full Text] [Related]
33. RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis.
Klein AL; Imazio M; Brucato A; Cremer P; LeWinter M; Abbate A; Lin D; Martini A; Beutler A; Chang S; Fang F; Gervais A; Perrin R; Paolini JF
Am Heart J; 2020 Oct; 228():81-90. PubMed ID: 32866928
[TBL] [Abstract][Full Text] [Related]
34. Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist.
Garg M; de Jesus AA; Chapelle D; Dancey P; Herzog R; Rivas-Chacon R; Muskardin TLW; Reed A; Reynolds JC; Goldbach-Mansky R; Sanchez GAM
JCI Insight; 2017 Aug; 2(16):. PubMed ID: 28814674
[TBL] [Abstract][Full Text] [Related]
35. Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis.
Schwier NC
Ann Pharmacother; 2022 May; 56(5):572-581. PubMed ID: 34459270
[TBL] [Abstract][Full Text] [Related]
36. Rilonacept for the treatment of recurrent pericarditis.
Fava AM; Reyaldeen R; Lo Presti S; Goyal A; Akintoye E; Hughes D; Klein AL
Expert Opin Biol Ther; 2022 Jan; 22(1):7-16. PubMed ID: 34757872
[TBL] [Abstract][Full Text] [Related]
37. Sustained Pericarditis Recurrence Risk Reduction With Long-Term Rilonacept.
Imazio M; Klein AL; Brucato A; Abbate A; Arad M; Cremer PC; Insalaco A; LeWinter MM; Lewis BS; Lin D; Luis SA; Nicholls SJ; Sutej P; Wasserstrum Y; Clair J; Agarwal I; Wang S; Paolini JF;
J Am Heart Assoc; 2024 Mar; 13(6):e032516. PubMed ID: 38471825
[TBL] [Abstract][Full Text] [Related]
38. New Indication for Rilonacept.
Aschenbrenner DS
Am J Nurs; 2021 Jul; 121(7):24-25. PubMed ID: 34156376
[TBL] [Abstract][Full Text] [Related]
39. The Role of Rilonacept in Recurrent Pericarditis.
Presti SL; Elajami TK; Reyaldeen R; Anthony C; Klein AL
Heart Int; 2021; 15(1):20-25. PubMed ID: 36277322
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]